Pipeline

Umoja’s VivoVec-driven pipeline is driving numerous near-term catalysts

Program
Preclinical
PHASE 1​
UB-VV400/410 NHL/Autoimmune
Preclinical
PHASE 1​
Target

CD22

Milestone

Clinic 2025

In-Licensing Partner

IASO Biotherapeutics

NCT06743503
UB-VV300/310 NHL/Autoimmune
Preclinical
PHASE 1​
Target

CD20

Milestone

IND enabling

UB-VV500 Multiple Myeloma
Preclinical
PHASE 1​
Target

Undisclosed

Milestone

IND enabling

UB-VV111 Hematology
Preclinical
PHASE 1​
Target

CD19

Milestone

Clinic 2025

Out-Licensing Partner

AbbVie

NCT06528301
Multiple Hematology
Preclinical
PHASE 1​
Target

Undisclosed

Milestone

Early development

Out-Licensing Partner

AbbVie

Multiple Oncology
Preclinical
PHASE 1​
Target

Undisclosed

Milestone

Early development

Out-Licensing Partner

AbbVie

Expanded Access & Compassionate Use Policy
 
Umoja Biopharma is committed to developing innovative therapies through rigorous clinical research that address critical unmet needs. Currently, we do not offer access to our investigational therapies outside of clinical trials. We believe that participation in clinical trials is the most appropriate and equitable pathway for patients to access our investigational therapies until the safety and tolerability of each has been established and evaluated by regulatory authorities.
 
For more information about our ongoing studies, please visit clinicaltrials.gov. Search “Umoja” to find our clinical trials that may be recruiting. If you are a healthcare professional and would like more information on our investigational therapies, please send an inquiry to info@umoja-biopharma.com.